Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of CDCP1 by 8-isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment.

Molecular oncology - 1 Aug 2023

Wong Sze-Ching, Yeh Chun-Chieh, Zhang Xun-Yu, Hsieh Chih-Ying, Lo Chia-Chien, Kuo Ting-Ting, Lin Ching-Chan, Chao Chih-Hua, Liu Jing-Pei, Chang Ling-Chu, Wang Lu-Hai, Sher Yuh-Pyng

Abstract excerpt

CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance by regulating EGFR signaling pathways and is a potential target in lung cancer treatment. This study aims to identify a CDCP1 reducer that synergistically improves TKI treatment. Utilizing a high-throughput drug screening system, a phytoestrogen 8-isopentenylnaringenin (8PN)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cell Adhesion Molecules

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Necrosis

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 37013960
DOI: 10.1002/1878-0261.13429
PMCID: PMC10399713

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of CDCP1 by 8-isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment.PMID 37013960Read ↗

Bioinformatic and experimental findings to indicate anti-cancer targets and mechanisms of calycosin against nasopharyngeal carcinomaSemantic proximity Read ↗

Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung CancerSemantic proximity Read ↗

Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental EvaluationSemantic proximity Read ↗

Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Herbal formula Yangyinjiedu induces lung cancer cell apoptosis via activation of early growth response 1Semantic proximity Read ↗

Inhibitory Effects of Metabolites of 5-Demethylnobiletin on Human Nonsmall Cell Lung Cancer CellsSemantic proximity Read ↗

Transcriptional signature of early cisplatin drug-tolerant persister cells in lung adenocarcinomaSemantic proximity Read ↗

Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screeningSemantic proximity Read ↗

A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

A novel selective ERK1/2 inhibitor, Laxiflorin B, targets EGFR mutation subtypes in non-small-cell lung cancer.Semantic proximity Read ↗

Synthetic lethality in lung cancer and translation to clinical therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.